Please select the option that best describes you:
When is lanreotide preferred over octreotide in GI neuroendocrine tumors?
Answer from: Medical Oncologist at Academic Institution
As far as I am concerned, the drugs are equally effective, assuming the drugs get delivered correctly. The advantages of lanreotide are, as others have mentioned, a more reliable delivery method being given SC instead of IM. Also, lanreotide has faster absorption and it takes a shorter time to achie...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
Currently, there is no evidence to favor one SSA over the other. Both randomized trials (PROMID and CLARINET) showed improved PFS with octreotide and lanreotide. However, both trials had differences in patient population, functionality, and liver tumor burden, we can't select one SSA over the other ...
Answer from: Medical Oncologist at Academic Institution
Obesity can be an issue for IM injections with Sandostatin. Tough to reach the muscle and a good reason to switch to a sub-q formulation.
Comments
Medical Oncologist
One must keep in mind that octreotide is only indi...
One must keep in mind that octreotide is only indi...
Answer from: Medical Oncologist at Academic Institution
Patient preference. I had a patient who developed an abscess after Sandostatin, which is a deep IM injection.